Ascent Group LLC Trims Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Ascent Group LLC decreased its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 10.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 5,389 shares of the financial services provider’s stock after selling 657 shares during the period. Ascent Group LLC’s holdings in iShares Biotechnology ETF were worth $739,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. boosted its position in shares of iShares Biotechnology ETF by 5.5% in the 4th quarter. First Horizon Advisors Inc. now owns 2,193 shares of the financial services provider’s stock worth $298,000 after purchasing an additional 115 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC boosted its position in shares of iShares Biotechnology ETF by 8.3% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,931 shares of the financial services provider’s stock worth $262,000 after purchasing an additional 148 shares in the last quarter. Corient Private Wealth LLC boosted its position in shares of iShares Biotechnology ETF by 1.0% in the 4th quarter. Corient Private Wealth LLC now owns 86,700 shares of the financial services provider’s stock worth $11,778,000 after purchasing an additional 841 shares in the last quarter. Great Valley Advisor Group Inc. boosted its position in shares of iShares Biotechnology ETF by 14.1% in the 4th quarter. Great Valley Advisor Group Inc. now owns 2,786 shares of the financial services provider’s stock worth $378,000 after purchasing an additional 344 shares in the last quarter. Finally, StrategIQ Financial Group LLC boosted its position in shares of iShares Biotechnology ETF by 9.2% in the 4th quarter. StrategIQ Financial Group LLC now owns 5,013 shares of the financial services provider’s stock worth $681,000 after purchasing an additional 422 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of IBB traded down $0.10 during mid-day trading on Tuesday, reaching $147.81. The company had a trading volume of 221,933 shares, compared to its average volume of 1,608,382. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $149.53. The firm has a 50-day moving average price of $138.95 and a 200 day moving average price of $136.02.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.